[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"t-lymphoblastic-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:t-lymphoblastic-lymphoma":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,80,132,152,173,199,226,249,276],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100645083","phase-1-a-multicenter-open-label-non-randomized-single-arm-phase-12-study-of-autologous-nano-cd5-car-t-cells-for-the-treatment-of-relapsedrefractory-t-cell-acute-lymphoblastic-leukemialymphoma-100645083",false,"NCT07678307","A Multicenter, Open-label, Non-randomized, Single-arm Phase 1\u002F2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia\u002FLymphoma","A Multicenter, Open-Label, Non-Randomized, Single-Arm Phase 1\u002F2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed\u002FRefractory T-Cell Acute Lymphoblastic Leukemia\u002FLymphoma","Inclusion Criteria:\n\n* Age 3 to 70 years old\n* Diagnosed with CD5-positive relapsed\u002Frefractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)\n* ECOG performance status 0-2\n* Adequate organ function (renal, hepatic, cardiac, pulmonary)\n* Able to understand and sign informed consent\n\nExclusion Criteria:\n\n* Active severe infection or uncontrolled sepsis\n* History of allogeneic stem cell transplantation within 3 months\n* Severe autoimmune disease or immunodeficiency\n* Prior CD5-targeted therapy\n* Pregnant or breastfeeding women\n* Any condition that, in the investigator's opinion, would compromise safety or compliance with the protocol","ALL","3 Years","70 Years",{"count":20,"type":21},18,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a clinical research study for people with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoma.\n\nThe study will test a new treatment called \"autologous nano CD5-CAR T cells\". These are your own immune cells that have been changed in a lab to recognize and kill cancer cells.\n\nThis study has two parts: Phase 1 to test the safety and best dose of the treatment, and Phase 2 to see how well it works.\n\nYou may receive the study treatment if you meet all the eligibility criteria. The main things the study will look at are: how safe the treatment is, how many people's cancer goes away or gets better, and how long the effect lasts.\n\nPossible risks include fever, low blood pressure, and infection, which the study team will monitor closely.",[28,29,30],"T-Cell Acute Lymphoblastic Leukemia","T-Lymphoblastic Lymphoma","Relapsed\u002FRefractory Hematologic Malignancies",[32,33,34,35,36,37],"CD5-CAR-T Cell Therapy","Nano CAR-T","Relapsed Refractory T-ALL","Relapsed Refractory T-Lymphoblastic Lymphoma","Phase 1\u002F2 Clinical Trial","Hematologic Malignancies","NOT_YET_RECRUITING","2026-06-25",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":21},"2026-06-30",{"date":46,"type":21},"2027-12-31",{"name":48,"class":49},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100598522","phase-2-testing-the-addition-of-daratumumab-to-chemotherapy-for-treating-patients-with-newly-diagnosed-t-cell-lymphoblastic-leukemia-t-all-and-t-cell-lymphoblastic-lymphoma-t-ll-100598522","NCT07072585","Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","A Phase 2\u002F3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)","Inclusion Criteria:\n\n* All patients must be enrolled on APEC14B1 and consented to eligibility screening (part A) prior to treatment and enrolled on AALL2331.\n* Patients must be \\> 365 days and \\\u003C 21 years of age at the time of diagnosis.\n* \\* Newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-lineage lymphoblastic lymphoma (T-LL) stages II-IV.\n\n  * Note: A diagnosis of T-ALL is established when leukemic blasts lack myeloperoxidase or evidence of B-lineage derivation (CD19\u002FCD22\u002FCD20), and express either surface or cytoplasmic CD3 or two or more of the antigens CD8, CD7, CD5, CD4, CD2 or CD1a, and are present either in peripheral blood or \\> 25% in the bone marrow. If surface CD3 is expressed on all leukemic cells, additional markers of immaturity, including TdT, CD34 or CD99 will be assessed for expression. Cases with uncertain expression will receive additional review within the appropriate Children's Oncology Group (COG) reference laboratory.\n  * For T-LL patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to T-ALL. For tissue processed by other means (i.e. paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of T-LL defined by the submitting institution will be accepted.\n\nExclusion Criteria:\n\n* Diagnosis of Down syndrome (trisomy 21).\n* Patients with known Charcot-Marie-Tooth disease.\n* \\* Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of T-ALL, T-LL or for any cancer diagnosis prior to the initiation of protocol therapy on AALL2331 with the exception of:\n\n  * Steroid pretreatment: Prednisone or methylprednisolone for ≤ 120 hours (5 days) in the 7 days prior to initiating induction chemotherapy or for ≤ 336 hours (14 days) in the 28 days prior to initiation of protocol therapy does not affect eligibility.\n  * Intrathecal cytarabine; or\n  * Pretreatment with hydroxyurea; or\n  * 600 cGy of chest irradiation, if medically necessary.\n  * Pre-treatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone used during sedation to prevent or treat airway edema. Patients who receive a single dose of dexamethasone to prevent or treat airway edema in the 28 days preceding diagnosis are eligible for this study.\n* \\* Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential.\n\n  * Lactating females who plan to breastfeed their infants.\n* Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation.\n* Known severe persistent asthma anytime in the previous two years or uncontrolled asthma of any classification.\n* Peripheral neurotoxicity: Pre-existing ≥ grade 2 sensory or motor peripheral neurotoxicity.\n* Seizure disorder: Patients must not have an uncontrolled seizure disorder. Patients with a seizure history or a controlled seizure disorder are eligible. A controlled seizure disorder is defined as having stable or decreasing symptoms over the past 3 months without anti-epileptic medications or is on a stable or decreasing dose of anti-epileptic medication.\n* \\* Patients who are previously known to be seropositive for HIV except for HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of enrollment on this trial.\n\n  * Patients with evidence of chronic hepatitis B (HBV) infection, except for patients who have an HBV viral load that is undetectable on suppressive therapy.\n  * Patients with a history of hepatitis C virus (HCV) infection, except for those patients who have been treated and cured, or patients who are currently on HCV treatment who have an undetectable HCV viral load.\n* Patients with significant hepatic dysfunction defined as those with an alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) \\> 10x upper limit of normal (ULN) or direct bilirubin \\> 2x ULN unless the patient has known Gilbert's syndrome or has hepatic involvement from leukemic or lymphomatous infiltration.\n* All patients and\u002For their parents or legal guardians must sign a written informed consent.\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met.","365 Days","21 Years",{"count":60,"type":21},1708,[25,62],"PHASE3","This phase II\u002FIII trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.",[65,66,67,68,69],"Stage II T Lymphoblastic Leukemia\u002FLymphoma","Stage III T Lymphoblastic Leukemia\u002FLymphoma","Stage IV T Lymphoblastic Leukemia\u002FLymphoma","T Acute Lymphoblastic Leukemia","T Lymphoblastic Lymphoma","2026-06-15",{"date":72,"type":42},"2026-06-17",{"date":74,"type":21},"2026-08-28",{"date":76,"type":21},"2035-09-01",{"name":78,"class":79},"Children's Oncology Group","NETWORK",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":102,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":131},"100633197","phase-1-adaptive-dual-target-car-t-cells-for-relapsed-or-refractory-hematologic-malignancies-100633197","NCT07523555","Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","A Phase 1\u002F2, Open-Label, Nonrandomized, Multi-arm Umbrella Study of Biomarker-Selected Dual-Target CAR-T Cell Modules in Adults With Relapsed or Refractory Hematologic Malignancies","ADAPT-HEM","Inclusion Criteria:\n\n* Age 18 to 75 years at the time of consent.\n* Pathologically or cytologically confirmed eligible disease: B-ALL; B-cell NHL\u002FCLL\u002FSLL; multiple myeloma\u002Fplasma cell leukemia; AML\u002Fhigh-risk MDS\u002FBPDCN; or T-ALL\u002FT-LBL\u002Fperipheral T-cell lymphoma.\n* Relapsed or refractory disease after at least 2 prior lines of therapy, or no curative\u002Fapproved standard option judged appropriate by the investigator.\n* Central laboratory confirmation that at least one active dual-target module is suitable based on malignant-cell antigen co-expression and safety review.\n* Measurable or otherwise evaluable disease by disease-specific response criteria.\n* ECOG performance status 0 to 2.\n* Adequate organ function: LVEF \\>= 45%; creatinine clearance \\>= 40 mL\u002Fmin; AST\u002FALT \\\u003C= 3 x ULN; total bilirubin \\\u003C= 1.5 x ULN unless due to Gilbert syndrome; oxygen saturation \\>= 92% on room air.\n* Adequate hematologic reserve unless cytopenia is clearly disease-related.\n* Ability to undergo leukapheresis and willingness to comply with study procedures and follow-up.\n* If prior allogeneic HSCT: at least 100 days from transplant, no uncontrolled GVHD, and no systemic immunosuppression above physiologic steroid replacement.\n* Negative pregnancy test for participants of childbearing potential and agreement to use effective contraception during protocol-defined risk periods.\n* Written informed consent obtained before any study-specific procedure.\n\nExclusion Criteria:\n\n* \\- Active uncontrolled infection, including uncontrolled bacterial, fungal, or viral infection, or clinical sepsis.\n* Active symptomatic CNS involvement requiring escalating therapy; previously treated\u002Fstable CNS disease may be allowed if defined prospectively in the final protocol.\n* Prior gene-modified cellular therapy within 12 weeks before leukapheresis, or unresolved \\>= Grade 3 toxicity from prior anticancer therapy\n* Need for urgent cytoreduction such that manufacturing delay would create unacceptable clinical risk.\n* Active autoimmune disease requiring systemic immunosuppression, except limited replacement-dose steroids or protocol-permitted topical\u002Finhaled therapy.\n* Prior solid organ transplant.\n* Clinically significant cardiovascular disease, uncontrolled arrhythmia, decompensated heart failure, myocardial infarction within 6 months, or recent stroke within 6 months.\n* Uncontrolled HIV, HBV, or HCV viremia.\n* Pregnancy or breastfeeding.\n* Another active malignancy requiring systemic therapy, unless low-risk and definitively treated per protocol-defined exceptions.\n* Known hypersensitivity to fludarabine, cyclophosphamide, or critical product excipients.\n* Inability to manufacture a releaseable CAR-T product or failure to meet module-specific product-release criteria.\n* Any medical, psychiatric, or social condition that, in the investigator's judgment, would increase risk, impair compliance, or confound interpretation of study results.","18 Years","75 Years",{"count":91,"type":21},96,[24,25],"Phase 1\u002F2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19\u002FCD22, CD19\u002FCD20, BCMA\u002FCD19, BCMA\u002FCD38, BCMA\u002FGPRC5D, CD33\u002FCD123, CD33\u002FCLL1, or CD5\u002FCD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, including overall response rate and MRD-negative response.\n\nLymphodepletion with fludarabine\u002Fcyclophosphamide precedes infusion. The design is intended to reduce antigen escape by matching disease biology and target co-expression to a rational dual-target strategy.",[95,96,97,98,99,100,101],"Relapsed\u002FRefractory B-cell Acute Lymphoblastic Leukemia","Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma or CLL\u002FSLL","Relapsed\u002FRefractory Multiple Myeloma or Plasma Cell Leukemia","Relapsed\u002FRefractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm","BPDCN; Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia","T-lymphoblastic Lymphoma","Peripheral T-cell Lymphoma",[103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119],"BCMA","biomarker-selected","CD19","CD20","CD22","CD33","CD38","CD123","CD5","CD7","CLL1\u002FCLEC12A","dual-target CAR-T","GPRC5D","hematologic malignancy","MRD negativity","antigen escape","umbrella trial","RECRUITING","2026-04-05",{"date":123,"type":42},"2026-04-13",{"date":125,"type":42},"2026-03-02",{"date":127,"type":21},"2028-02-17",{"name":129,"class":130},"Beijing Biotech","INDUSTRY",1,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":88,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":4},"100629542","early-phase-1-efficacy-and-safety-of-cd7-car-t-in-newly-diagnosed-high-risk-t-lblall-100629542","NCT07476027","Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL\u002FALL","Efficacy and Safety of CD7 CAR-T Cell in Newly Diagnosed High-Risk T-LBL\u002FALL","Inclusion Criteria:\n\n* Patients aged ≤18 years with newly diagnosed T-LBL\u002FALL.\n* Have completed induction chemotherapy and achieved CR1, with bone marrow MRD \\\u003C 0.01%.\n* High\u002Fvery high-risk or poor induction response patients.\n* High risk of future relapse, and recommended by multidisciplinary team (MDT) evaluation for prospective lymphocyte collection and preparation.\n* Peripheral blood absolute lymphocyte count (ALC) ≥ 0.5×10⁹\u002FL, and good general condition (ECOG score 0-1 or Lansky\u002FKarnofsky score ≥ 80).\n* Legal guardian agrees to provide written informed consent.\n\nInfusion Criteria:\n\n* Essential normal function of major organs.\n* Left ventricular ejection fraction (LVEF) ≥ 45%.\n* Serum creatinine ≤ 1.5 × upper limit of normal (ULN) for age.\n* Serum total bilirubin, ALT\u002FAST ≤ 3 × ULN (unless clearly related to leukemic infiltration).\n* No active, uncontrolled severe infection.\n\nExclusion Criteria:\n\n* Severe cardiac or pulmonary insufficiency, which the investigator deems inappropriate for enrollment.\n* Complicated with other progressive malignant tumors.\n* Presence of active and\u002For uncontrolled infections that have not been effectively managed.\n* Complicated with severe autoimmune diseases or congenital immunodeficiency.\n* Active hepatitis \\[positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), with HBV DNA copy number greater than the upper limit of normal at the study center; positive for anti-HCV, with HCV-RNA copy number greater than the upper limit of normal at the study center\\].\n* Human immunodeficiency virus (HIV) infection or known acquired immune deficiency syndrome (AIDS), syphilis infection.).\n* A history of severe hypersensitivity to biological products (including antibiotics).\n* Patients who have undergone allogeneic hematopoietic stem cell transplantation and still suffer from acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents.\n* Patients with other severe physical or mental diseases or abnormal laboratory test results that may increase the risk of study participation or interfere with study outcomes, as well as those who are deemed unsuitable for participation in this study by the investigator.",{"count":5,"type":21},[141],"EARLY_PHASE1","This study is an open, single-center, prospective clinical trial, with newly diagnosed high-risk T-LBL\u002FALL patients as the subjects. It plans to enroll 10 subjects. All patients will undergo lymphocyte collection during the CR1 remission period, followed by the preparation and reinfusion of CD7 CAR-T cells. Adverse reactions will be followed up and observed, and relevant data on treatment efficacy will be collected to evaluate the safety, efficacy, and cell metabolic kinetics characteristics of CAR-T cell therapy for the patients.",[69,68],"2026-03-12",{"date":146,"type":42},"2026-03-17",{"date":148,"type":21},"2026-03-15",{"date":150,"type":21},"2029-06-27",{"name":48,"class":49},{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":131},"100095334","phase-2-combination-chemotherapy-and-nelarabine-in-treating-patients-with-t-cell-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma-100095334","NCT00501826","Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma","Inclusion Criteria:\n\n* Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to one induction course of chemotherapy are eligible; patients in CR after =\\\u003C 2 courses are also eligible\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3\n* Serum bilirubin less than or equal to 2.0 mg\u002FdL unless considered due to involvement by tumor when an upper limit of 5.0 mg\u002FdL is acceptable\n* Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)\n* Serum creatinine less than or equal to 2.0 mg\u002FdL unless considered due to involvement by tumor when an upper limit of 2.5 mg\u002FdL is acceptable\n\nExclusion Criteria:\n\n* Pregnant or nursing women",{"count":160,"type":21},160,[25],"This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.",[68,69],"2026-01-05",{"date":166,"type":42},"2026-01-07",{"date":168,"type":42},"2007-07-11",{"date":170,"type":21},"2026-10-31",{"name":172,"class":49},"M.D. Anderson Cancer Center",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100386714","phase-1-study-to-test-obi-3424-in-patients-with-t-cell-acute-lymphoblastic-leukemia-t-all-or-t-cell-lymphoblastic-lymphoma-t-lbl-100386714","NCT04315324","Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)","A Phase I\u002FII Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients With Relapsed\u002FRefractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)\u002FT-Cell Lymphoblastic Lymphoma (T-LBL)","Inclusion Criteria:\n\n* Patients must have a diagnosis of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) based on World Health Organization (WHO) classification. Patients with relapsed\u002Frefractory T-cell lymphoblastic lymphoma are eligible if lymphoblasts are \\>= 5% in the bone marrow or in the peripheral blood by morphology or flow cytometry\n* Patients must have evidence of acute leukemia in their peripheral blood or bone marrow. Patients must have \\>= 5% lymphoblasts in the peripheral blood or bone marrow within 14 days prior to registration. Patients with only extramedullary disease are not eligible\n* Patients ≥ 18 years of age must be refractory to or have relapsed following a standard induction chemotherapy. Patients \\\u003C 18 years of age must have relapsed or must be refractory after 2 or more chemotherapy cycles (example: induction and consolidation)\n\n  * A standard chemotherapy induction regimen is defined as any program of treatment that includes:\n\n    * Vincristine and corticosteroids plus at least one more chemotherapy agent\n    * Cytarabine and anthracycline, or\n    * High dose cytarabine (defined as at least 1 gr\u002Fm\\^2 per individual dose unless adjustments were required for renal\u002Fliver function)\n* Patients must have no evidence of central nervous system disease within 28 days prior to registration based on cerebrospinal fluid (CSF) studies. Patients with clinical signs or symptoms consistent with central nervous system (CNS) involvement must have a lumbar puncture which is negative for CNS involvement; the lumbar puncture must be completed within 28 days prior to registration. Patients with CNS1 or CNS2 are eligible; however patients with CNS3 are not eligible\n* Note that the patients may receive intrathecal chemotherapy with the initial lumbar puncture. This may count as the first dose of intrathecal therapy required as part of the study\n* Prior nelarabine therapy is not required. In addition, for patients ≥ 18 years of age who received nelarabine during initial induction or post-remission treatment are eligible only if the physician does not feel they would benefit from other, multi-agent chemotherapy\n* Patients must not have had chemotherapy or investigational agents within 14 days prior to registration except for corticosteroids, oral 6-mercaptopurine, oral methotrexate, vincristine, intrathecal chemotherapy, or hydroxyurea. For participants who have received radiation therapy, at least 7 days must have elapsed from the end of radiation prior to registration and participants must not currently be experiencing toxicities from radiation therapy\n* Patients must not have undergone allogeneic hematopoietic transplant within 90 days prior to registration\n* Patients must have no evidence of active \\>= grade 2 acute graft versus host disease (GVHD) or moderate or severe limited chronic GVHD. Patients must have no history of extensive GVHD of any severity within 90 days prior to registration. Patients who are post-transplant must be off calcineurin inhibitors for at least 21 days to be eligible. Extensive GVHD is defined as 1) generalized skin involvement or 2) localized skin involvement and\u002For hepatic dysfunction plus liver histology or cirrhosis or involvement of eye or minor salivary organ or oral mucosa or any other target organ\n* Patients must be \\>= 12 years of age\n* Patients ≥ 16 years of age must have a Zubrod Performance Status of 0-3. Patients \\\u003C 16 years of age must have a Lansky score of ≥ 50\n* Patients must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs\u002Fsymptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) within 14 days prior to registration\n* Patients ≥ 18 years of age must have creatinine clearance \\> 30 mL\u002Fmin within 14 days prior to registration according to the Cockcroft Gault equation\n* Patients 12-17 years of age must have adequate renal function within 14 days prior to registration defined as serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN) according to age or a calculated estimated glomerular filtration rate (eGFR) (based on Schwartz formula) or radioisotope glomerular filtration rate (GFR) ≥ 50ml\u002Fmin\u002F1.73 m\\^2\n* Patients must have direct bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN) within 14 days prior to registration\n* Patients must have alanine aminotransferase (ALT) =\\\u003C 3.0 x institutional upper limit of normal (ULN) or =\\\u003C 5.0 x ULN (if thought to be related to leukemic involvement) within 14 days prior to registration\n* Prothrombin time (PT)\u002Fpartial thromboplastin time (PTT)\u002F fibrinogen (as clinically indicated for example but not limited to history of bleeding or active bleeding, concern for disseminated intravascular coagulation) (within 14 days prior to registration to obtain baseline measurements)\n* From metabolic panel (comprehensive or basic): sodium, potassium, chloride, carbon dioxide (CO2), and blood urea nitrogen (BUN) (within 14 days prior to registration to obtain baseline measurements)\n* Patients must be able to safely discontinue use of strong inhibitors\u002Finducers of CYP3A4 or PgP-g-p and must be able to safely discontinue use of naproxen for 48 hours before and after each dose of OBI-3424\n* Patients with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test within 6 months prior to registration. (HIV viral load testing is required only for patients with known HIV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4\n* Patients with evidence of chronic hepatitis B virus (HBV) infection may be eligible provided that they have an undetectable HBV viral load within 28 days prior to registration. Patients may be currently receiving HBV treatment. (HBV viral load testing is required only for patients with known HBV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4\n* Patients with known history of hepatitis C virus (HCV) infection may be eligible provided that they have an undetectable HCV viral load within in 28 days prior to registration. Patients may be currently receiving treatment. (HCV viral load testing is required only for patients with known HCV infection). Patients must not be receiving antiviral therapies that are known strong inhibitors or inducers of CYP3A4\n* Patients must not have a known history of prolonged QT interval by Fridericia (QTcF) (interval \\> 450 msec for males; \\> 470 msec for females). Patients that had transient prolongation of QTc secondary to medications or electrolyte abnormalities are not excluded if the QTc normalized and remain within acceptable QTcF range (interval \\> 450 msec for males; \\> 470 msec for females). Additionally, suspected medications should be no longer required or used, and electrolyte abnormalities must have normalized\n* Patients must not be pregnant or nursing due to the teratogenic potential of the drug used on this study. Females of reproductive potential must have a negative serum pregnancy test within 14 days prior to registration. Women\u002Fmen of reproductive potential must have agreed to use an effective contraceptive method during and up to 6 months after treatment. A woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, \"effective contraception\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he\u002Fshe is responsible for beginning contraceptive measures\n* Patients must not have other active malignancies for which they have received treatments within 6 months prior to registration excluding localized malignancies that do not require systemic treatment\n* Patients must agree to have bone marrow and blood specimens submitted for MRD testing\n* Patients must be offered the opportunity to participate in specimen banking. With patient consent, residuals from specimens submitted will be retained and banked for future research\n* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with fedral, local, institutional and Central Institutional Review Board (CIRB) guidelines unless they are unable to provide consent based on age (\\\u003C 18 years) or based on impaired decision-making capabilities. For patients \\\u003C 18 years of age or with impaired decision making capabilities, parents or other legally authorized representatives must sign and give informed consent on behalf of study participants in accordance with applicable federal, local, institutional and CIRB regulations\n* As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\n* This trial will use a slot reservation system to enroll the Phase I portion of the study. Patients planning to enroll at this phase of the study must first have a slot reserved in advance of the registration. All site staff will use OPEN to create a slot reservation","12 Years",{"count":182,"type":21},67,[24,25],"This phase I\u002FII trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.",[186,187,188,69],"Recurrent T Acute Lymphoblastic Leukemia","Refractory T Acute Lymphoblastic Leukemia","Refractory T Lymphoblastic Lymphoma","2025-08-11",{"date":191,"type":42},"2025-08-15",{"date":193,"type":42},"2021-02-08",{"date":195,"type":21},"2028-08-01",{"name":197,"class":79},"SWOG Cancer Research Network",163,{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":4},"100573095","allo-hsct-vs-asct-in-adult-t-lbl-100573095","NCT06741813","Allo-HSCT vs ASCT in Adult T-LBL","Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation for Adult T Lymphoblastic Lymphoma as First-line Consolidation.","TROPHY-NHL01","Inclusion Criteria:\n\n* 1\\) Newly diagnosed T-LBL; 2) 18-65 years of age at the time of diagnosis; 3) Categorized into Ann-Arbor stage III or IV; 4) Achieving complete response (CR) after 3 courses of induction chemotherapies; 5) ECOG PS score 0 or 1; 6) It needs consent from the patients or\u002Fand legal guardian, and signature on the Informed Consent.\n\nExclusion Criteria:\n\n* 1\\) Newly diagnosed T-LBL, but categorized into Ann-Arbor stage I or II; 2) \\\u003C 18 years, or older than 65 years at the time of diagnosis; 3) Achieving CR after 4 or more courses of induction chemotherapies, or could not achieve at least CR after induction chemotherapies; 4) with \\> 25% BM involvement or \\> 5% lymphoma cells in the peripheral blood; 5) ECOG PS score of 2 or more; 6) Patients with other comorbidities or mental diseases that influence the life safety and compliance of patients as well as affect informed consent, enrollment in the research, follow-up visit or result interpretation.","65 Years",{"count":209,"type":21},230,[211],"NA","Autologous hematopoietic stem cell transplantation (ASCT) is the important consolidation for adult T-LBL. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is also the important consolidation for adult T-LBL. So ASCT vs allo-HSCT: which is better consolidation for adult T-LBL?",[69],[215,216,69],"allogeneic hematopoietic stem cell transplantation","Autologous hematopoietic stem cell transplantation","2024-12-15",{"date":219,"type":42},"2024-12-19",{"date":221,"type":21},"2025-01-01",{"date":223,"type":21},"2029-12-31",{"name":225,"class":49},"Peking University People's Hospital",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":131},"100564758","early-phase-1-targeting-cd5-car-t-cells-in-the-treatment-of-rr-cd5-t-lymphoma-100564758","NCT06633341","Targeting CD5 CAR-T Cells in the Treatment of r\u002Fr CD5+ T-lymphoma","A Clinical Study on the Safety and Effectiveness of Targeting CD5 CAR-T Cells in the Treatment of r\u002Fr CD5+ T-lymphoma","Inclusion Criteria:\n\n* 1\\. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),\n\nR\u002FR T-NHL(meets one of the following conditions) :\n\n1. Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;\n2. Primary drug resistance;\n3. Relapse after autologous hematopoietic stem cell transplantation;\n\n   * 2.CD5 expression rate was \\>90%;\n   * 3\\. According to Lugano 2014, there should be at least one evaluable tumor lesion;\n   * 4\\. Total bilirubin ≤51 (mol\u002FL), Alanine aminotransferase (ALT)\u002FAspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol\u002FL);\n   * 5\\. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;\n   * 6\\. Refers to the pulse oxygen saturation 92% or higher oxygen (state);\n   * 7\\. Estimated life expectancy of minimum of 12 weeks;\n   * 8\\. ECOG 0-2;\n   * 9\\. Pregnant\u002Flactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;\n   * 10\\. Those who voluntarily participated in this trial and provided informed consent;\n\nExclusion Criteria:\n\n* 1\\. History of epilepsy or other central nervous system disorders;\n* 2\\. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;\n* 3\\. Active infection of hepatitis B virus, C virus or hepatitis E virus;\n* 4\\. Active infected persons who are not cured;\n* 5\\. Before using any gene therapy products;\n* 6\\. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:\n\n  1. treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone \\\u003C 10 mg\u002Fd or an equivalent dose of the drug);\n  2. received within 72 hours of small molecule targeted therapy;\n  3. 2 weeks received systemic chemotherapy except (pretreatment);\n  4. four weeks received radiotherapy;\n* 7\\. The proiferation rate is less than 5 times response to CD3\u002FCD28 co-stimulation signal;\n* 8\\. Any unsuitable to participate in this trial judged by the investigator;\n* 9\\. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.",{"count":234,"type":21},30,[141],"A Clinical Study on the Safety and Effectiveness of targeting CD5 CAR-T Cells in the treatment of r\u002Fr CD5+ T-lymphoma",[100],[239],"CD5 CAR-T","2024-10-08",{"date":242,"type":42},"2024-10-09",{"date":244,"type":21},"2024-10-20",{"date":246,"type":21},"2027-10-20",{"name":248,"class":49},"Zhejiang University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":131},"100545040","phase-1-linperlisib-combined-with-camrelizumab-and-pegaspargase-in-advanced-or-relapsedrefractory-nkt-cell-lymphoma-100545040","NCT06376721","Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed\u002FRefractory NK\u002FT-cell Lymphoma","A Phase Ib\u002FII Clinical Trial of Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed\u002FRefractory NK\u002FT-cell Lymphoma","Inclusion Criteria:\n\n* Histopathology and immunohistochemistry confirmed diagnosis of ENKTL according to WHO 2016 criteria.\n* refractory or relapsed after initial remission, or Ann-Arbor stage III-IV de novo patients\n* PET\u002FCT or CT\u002FMRI with at least one objectively evaluable lesion.\n* Expected to survive more than 3 months.\n* General status ECOG score 0-2 points.\n* The laboratory test within 1 week before enrollment meets the following conditions:\n\nBlood routine: WBC≥3×10e9\u002FL, PLT≥75×10e9\u002FL, ANC≥1.5×10e9\u002FL. sCR≤1.5 mg\u002FdL,GFR≥50 ml\u002Fmin. Liver function: ALT \\& AST≤3 times the upper limit of normal, TBIL ≤2 times the upper limit of normal.\n\nSerum fibrinogen level≥1.0 g\u002FL.\n\n•Sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with CNS involvement, or with other neoplasm;\n* Patients has received PI3K inhibitor treatment before enrollment\n* Poor performance status, ECOG≥2;\n* Patients in lactation or pregnancy；\n* Patients (male or female) have the possibility of childbirth but are unwilling or have not taken effective contraceptive measures；\n* Patients allergic to any of the study drugs；\n* Patients with active infection；\n* Patients with a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;\n* Patients with a history of interstitial pneumonia, non infectious pneumonia, or highly suspected interstitial pneumonia;\n* Patients with a history of neurological or psychiatric disorders, including epilepsy or dementia, in the past\n* According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study.",{"count":257,"type":21},43,[24,25],"The patients diagnosed with relapsed\u002Frefractory or advanced NK\u002FT-cell Lymphoma (r\u002Fr NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r\u002Fr NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.",[261,100],"Natural Killer\u002FT-Cell Lymphoma, Nasal and Nasal-Type",[263,264,265,266],"r\u002Fr ENKTL","Linperlisib","PD-1 blockade","Pegaspargase","2024-04-17",{"date":269,"type":42},"2024-04-19",{"date":271,"type":42},"2024-04-14",{"date":273,"type":21},"2027-10-31",{"name":275,"class":49},"Beijing Tongren Hospital",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":131},"100526563","phase-1-cd7-car-t-in-adults-with-relapsed-or-refractory-t-lblall-clinical-study-100526563","NCT06136364","CD7 CAR-T in Adults With Relapsed or Refractory T-LBL\u002FALL Clinical Study","Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL\u002FALL","Inclusion Criteria:\n\nAccording to the WHO hematopoietic and lymphoid tissue tumors classification, Subjects with refractory\u002Frelapsing T-LBL\u002FALL has been adequately treated and there is a lack of effective treatment, met one of the following criteria:\n\n1. relapse: Primordial cells (\\>5%)in peripheral blood or bone marrow appeared again after complete remission with standard treatment or Extramedullary disease appears，include：\n\n   1. Early recurrence within 12 months，\n   2. Late recurrence at 12 months or above and with no remission after a course of standard induction chemotherapy，\n   3. Recurrence after autologous or allogeneic hematopoietic stem cell transplantation ;\n2. Refractory: patients who have received at least two courses standard induction regimen and failed to achieve a complete response or complete remission was not achieved after first-line or above salvage treatment;\n3. The tumor cells detected by bone marrow flow cytometry were CD7+ and\u002For extramedullary lesions were diagnosed as CD7+ by pathological immunohistochemistry at the time of enrollment and screening;\n4. If tumor cells were detected in peripheral blood during enrollment and screening, it was required to meet the requirement that the surface immunophenotype of tumor cells was CD4 and CD8 double negative by flow cytometry.\n5. Life expectancy greater than 12 weeks;\n6. ECOG 0-2;\n7. Age 18-75 (upper and lower limits included);\n8. HGB at least 70g\u002FL,PLT 50x109\u002FL, can be transfused;\n9. Liver and kidney functions The cardiopulmonary functions meet the following requirements:\n\n   1. Oxygen saturation under air ≥ 92%;\n   2. LVEF≥50%;\n   3. Total bilirubin \\\u003C3×ULN;\n   4. ALT\u002FAST\\\u003C3×ULN;\n   5. Creatinine \\\u003C1.5×ULN or creatinine clearance rate(Cockroft-Gault)\\>50ml\u002Fmin;\n10. Informed consent explained to, understood by and signed by patient\u002F guardian.\n\nExclusion Criteria:\n\nThose who meet any of the following criteria are not eligible to join the group:\n\n1. New York Heart Association (NYHA) classification ≥ grade III heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris or other clinically prominent heart disease within one year before signing the informed consent form, Or QTc interval \\>480ms at screening (QTc interval calculated by Fridericia formula);\n2. If the patient has a history of hematopoietic stem cell transplantation, 6 months after the patient received allogeneic hematopoietic stem cell transplantation;\n3. Those with active GvHD or those who require immunosuppressive therapy;\n4. Malignancy other than T-cell acute lymphoblastic leukemia\u002Flymphoma within 5 years prior to screening, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after radical surgery, radical surgery ductal carcinoma in situ;\n5. History of non-neoplastic central nervous system disease (Seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, neuropathy)\n6. Active or uncontrollable infection requiring systemic treatment within 7 days prior to screening (except for mild urogenital infections and upper respiratory tract infections);\n7. History of autoimmune disease (eg, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease) requiring systemic immunosuppressive\u002Fsystemic disease modulating medication within the past 2 years;\n8. When screening, if the hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HbcAb) is positive, and the peripheral blood hepatitis B virus (HBV) DNA is higher than the detection limit, it needs to be excluded; if the hepatitis C virus (HCV) antibody is positive, the peripheral blood HCV Those with positive RNA need to be excluded; those with positive human immunodeficiency virus (HIV) antibody; those with positive cytomegalovirus (CMV) DNA test; those with positive test for Treponema pallidum specific antibody (TPPA) need to be excluded;\n9. Participate in other clinical trials within 4 weeks before the informed consent is signed, or the date of the informed consent is signed and the last medication of the drug is still within 5 half-lives of the drug (whichever is longer);\n10. History of severe allergy to biological products;\n11. Unstable systemic disease as judged by the investigator: including but not limited to severe liver, kidney or metabolic disease requiring drug therapy;\n12. Pregnant or breastfeeding women, and female subjects planning pregnancy within 2 years of cell infusion or male subjects whose partner is planning pregnancy within 2 years of cell infusion;\n13. Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening;\n14. Circumstances that the investigator believes may increase the risk to the subject or interfere with the results of the trial.",{"count":284,"type":21},9,[24],"To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL\u002FALL.",[100,288],"T-ALL","2023-11-14",{"date":291,"type":42},"2023-11-18",{"date":293,"type":42},"2023-08-15",{"date":295,"type":21},"2038-08-14",{"name":297,"class":130},"Hebei Senlang Biotechnology Inc., Ltd."]